Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis
Summary
SAN FRANCISCO & MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )--Adynxx, Inc., a clinical-stage biotechnology company focused on pain and inflammation, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to develop an oral, non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve upon the standard of care.Under the agreement, twoXAR will use its proprietary AI technology to identify a set of drug candidates with the potential to treat or prevent the recurrence of endometriosis and associated symptoms.“Cutting-edge AI technologies like twoXAR’s can help generate a new understanding of biology and provide a sensitive prediction of the therapeutic benefit of potential drug candidates,” said Julien Mamet, PhD, founder and Chief Scientific Officer of Adynxx.“This collaboration is part of our plan to build a diverse pipeline of promising therapies to address unmet medical needs in pain and inflammatory diseases such as endometriosis.We believe the discovery strategy designed with twoXAR will allow us to identify and develop compounds with an accelerated timeline, decreased risk and reduced costs to address a serious health problem impacting millions of women in the US and worldwide.”